Kornimate/medical-research-clean huggingface dataset:
effects of senobi breathing exercises in obese women

Conditions: Obesity

Summary: previous studies have been done just in studying the relationship between breathing technique and obesity and described how it proved helpful in decreasing body fat. this study will be very helpful for future researchers as well as in filling the literature gap by explaining the importance of sbe (senobi breathing exercise) in correlation with increased body fat, compromised lung function and depression in females of age from 30 to 60 years.

the study is quasi-experimental study, which is being conducted in a private clinical settings in khushab. sample size of 20 individuals was calculated using hamilton depression scale with effect size 0.97 g power 3.1.9.2 software. the study participants will be screened first, then trained to perform sbe(1-minute maneuver). participants will be instructed to stand upright and tighten their gluteal muscle and then ask them to put one foot in front of their body and placing most of their body weight on back foot. then, ask them to breath in for three seconds simultaneously, by raising their hands in the air above their heads. after this, instruct them to exhale by using their whole body for pushing air out of the lungs. participants will also guided to tighten all their body muscles while pushing air out. exhale should last for seven seconds. the participants will also guided to repeat this procedure 3 times in one minute with resting period of 10 seconds. they will perform it 3 times a day for 3 months. assessments will be taken at baseline \& after 3 months.

Eligibility criteria:
inclusion criteria: * women of age between 30 to 60 years. * asian bmi (\> 27.5) * obese women with mild to moderate depression exclusion criteria: * sedentary lifestyle * following an unhealthy diet plan * any cardiopulmonary conditions * endocrine conditions: hypothyroidism
treatment of post-covid-19 with hyperbaric oxygen therapy: a randomized, controlled trial

Conditions: Post-COVID-19 Syndrome; Post-COVID Syndrome; Post COVID-19 Condition; Post-COVID Condition; Post COVID-19 Condition, Unspecified; Long COVID; Long Covid19

Summary: the goal of this clinical try is to investigate the effect of hyperbaric oxygen therapy (hbot) on symptoms, quality of life and absence of work through sickness in patients with post-covid on short- and mid-term, as well as to identify biochemical mechanisms of action. the main questions it aims to answer are: * what is the clinical relevance of improvements of symptoms and quality of life after treatment with hbot for post-covid? * what are the changes in absence from work after treatment with hbot? * what is the cost-effectiveness of treatment with hbot? * what are possible mechanisms of action of hbot? participants will undergo 40 sessions of hbot. researchers will compare hbot with standard care alone (control group). in case of a positive outcome, patients in the control group can cross-over to the hbot group after 6 months.


Eligibility criteria:
inclusion criteria: * cognitive and/or physical symptoms ≥ 12 months after acute covid-19 infection * symptoms include post-exertional malaise (pem) and/or dysautonomia as assessed by questionnaires and/or nasa lean test * symptoms affect day-to-day life (based on sf-36 'role limitations due to physical functioning' score of ≤ 50 at baseline). * current treatment regimen is stable for at least 1 months before inclusion exclusion criteria: * unfit for hyperbaric treatment * previous diagnosis of me/cfs * unable to provide informed consent

Keywords: clinical relevance quality of life absence from work cost-effectiveness
chronic thromboembolic disease registry

Conditions: Chronic Thromboembolic Pulmonary Hypertension; Chronic Thromboembolic Disease

Summary: the goal of this patient registry is to learn about the natural history in patients with chronic thromboembolic disease (ctd) and/or chronic thromboembolic pulmonary hypertension (cteph). the main question\[s\] it aims to answer are: * long-term outcome after various types of treatment, including medication, balloon pulmonary angioplasty, and pulmonary endarterectomy * effect of treatment on patient's quality of life and exercise tolerance participants will be followed longitudinally to assess their health outcomes and quality of life via chart review and health quality surveys.


Eligibility criteria:
inclusion criteria: * patients referred with cted and/or cteph defined as: 1. mean pulmonary arterial pressure (mpap) \> 20 mmhg at rest with pulmonary vascular resistance (pvr) \> 2 wood units (wu); or if mpap ≤ 20 mmhg or pvr ≤ 2 wu at rest, have exercise limitations from chronic thromboembolic pulmonary disease (ctepd) without pulmonary hypertension (ph) 2. radiologic finding of chronic thromboembolic disease, including abnormal ventilation perfusion scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram 3. post-embolic exercise intolerance and evidence of chronic thromboembolic disease in the absence of resting pulmonary hypertension * treatment with anticoagulation for ≥ 3 months before diagnosis of cteph or ctepd without ph * age ≥ 18 years exclusion criteria: * main cause of ph other than world health organization (who) group 4 (cteph) * patient's refusal to participate in clinical research and/or receive intervention
cancer, physical activity and quality of life- a longterm follow up

Conditions: Cancer; Rehabilitation; Stress Disorder; Fatigue; Quality of Life; Physical Activity

Summary: this project is a 6-8-years follow-up of a randomized controlled trial testing a stepped care stress management program. the main goal is to examining differences in long-term effects on cancer-related stress reactions and emotional reactivity between the intervention and control group. secondary objectives is to investigate consequences of cancer and its' treatment over time, such as long term quality of life, objectively physical activity and experiences concerning follow-up and the transition from specialist health services to municipal health services.

major improvements in cancer detection and treatment lead to longer life expectancy among cancer survivors. this may in turn lead to more late effects and many have to deal with long-term consequences of the disease and its' treatment. returning to everyday life and to work is often an important part of returning to normal life for cancer survivors. there is increasing knowledge concerning late effects, but there is still lack of knowledge concerning the life of those experiencing late effects. there is a need for more knowledge about late effects' impact on the return to work prosess, physical activity and quality of life over time. both quantitative and qualitative methods will be utilized. standardized questionnaires will provide information on the effect of the intervention over time, in addition to quality of life over time. sensewear armband will provide information about their physical activity over time. official register data from the norwegian labour and welfare administration (the nav administration) will provide us information about the work- and benefit situation through the whole follow-up period of 6-8 years. the register data include information about type of social benefits (sick-leave benefit, work assessment allowance (waa), disability pension, unemployment benefit and retirement pension), as well as information about occupation, income and sick leave diagnosis. focus group interviews will give us insight in the cancer survivors own experiences with quality of life over time, the transition from the specialist health services to the primary health care and the follow-up in the municipalities.

Eligibility criteria:
inclusion criteria: * stage i-iii disease * scheduled for neo/adjuvant or curative treatment (i.e. chemotherapy, radiation therapy or hormonal therapy or any combination of these therapies) exclusion criteria: * on-going psychiatric condition * lack of fluency in norwegian * a previous diagnosis of cancer
the association between time in range with markers of endothelial and cardiovascular function

Conditions: Type 1 Diabetes

Summary: in this observaltional study, 90 patients aged \>12 years old with t1dm who are on minimed 780g system will be included.we aim to investigate the association between time in range (70-140mg/dl) and time in tight range (70-180mg/dl) with markers of endothelial and cardiovascular function.

in this observational study, 90 participants with t1d on minimed 780g system will be included. hba1c, anthropometric measurements, cgm and insulin metrics will be assessed in all patients. moreover, the investigators will assess: 1. the pulse wave velocity, the augmentation index and the central systolic blood pressure which are markers of arterial stiffness 2. the perfused boundary region of subglingulal vessels which is marker of endothelial function 3. the global longitudinal strain which is marker of myocardial function.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of type 1 diabetes \>1 year prior to consent date. diagnosis of type 1 diabetes is based on the investigator's judgment; c peptide level and antibody determinations are not required. 2. hba1c \< 12.5% 3. age \>7years at the initiation of the system 4. multiple daily injections (basal bolus therapy) with total daily insulin use of great than 8.0 units per day over a 1-week period 5. clinically able to start the ahcl system 6. history of 3 clinic visits in the last year exclusion criteria: 1. diabetic ketoacidosis in the 6 months prior to screening visits
single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of amg 827

Conditions: Psoriasis

Summary: this phase 1 study will evaluate safety, tolerability, pk and pd of amg 827 when administered as a single sc or iv dose.

this phase 1 study will evaluate safety, tolerability, pk and pd of amg 827 when administered as a single sc or iv dose in healthy subjects (part a) and subjects with moderate to severe psoriasis (part b).

Eligibility criteria:
inclusion criteria: part a: * able to provide written informed consent * healthy male or female between 18 to 45 years of age, inclusive at the time of screening * additional inclusion criteria apply part b: * 18 - 55 years old inclusive at screening * active but clinically stable, plaque psoriasis * psoriasis involving ≥ 10% of the body surface area * a minimum pasi score of ≥ 10 obtained during the screening period * additional inclusion criteria apply exclusion criteria: part a: * history or evidence of a clinically significant disorder (including but not limited to cardiopulmonary, oncologic, renal, metabolic, hematologic or psychiatric), condition or disease that, in the opinion of the investigator and amgen physician would pose a risk to subject safety or interfere with the study evaluation, procedures or completion * underlying condition that predisposes the subject to infections (eg, uncontrolled diabetes - hba1c \> 7%, history of splenectomy) * additional exclusion criteria apply part b: * active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit * evidence of skin conditions other than psoriasis (eg, eczema) at the time of the screening visit or between the screening visit and study drug initiation that would interfere with evaluations of the effect of investigational product on psoriasis * any condition that, in the judgment of the investigator, might cause this study to be detrimental to the subject * additional exclusion criteria apply
duloxetine as an analgesic agent in patients undergoing elective spine surgery

Conditions: Intervertebral Disc Degeneration

Summary: duloxetine as an analgesic agent in patients undergoing elective spine surgery: evaluation with fentanyl demand controlled by the patient. the primary objective is to evaluate the efficacy of duloxetine in fentanyl consumption during the postoperative period of patients undergoing elective spine surgery by intervertebral disc degeneration . secondary endpoints were pain scores and the presence or absence of adverse effects such as headache, nausea, vomiting, itching, dizziness and drowsiness.

multimodal analgesia is widely advocated for the control of perioperative pain in an attempt to reduce the use of opioids and their side effects. duloxetine is a selective inhibitor of serotonin and norepinephrine reuptake with demonstrated efficacy in chronic pain such as painful diabetic neuropathy and postherpetic neuralgia. the primary objective is to evaluate the efficacy of duloxetine in fentanyl consumption during the postoperative period of patients undergoing elective spine surgery by intervertebral disc degeneration . duloxetine as an analgesic agent in patients undergoing elective spine surgery: evaluation with fentanyl demand controlled by the patient. the primary objective is to evaluate the efficacy of duloxetine in fentanyl consumption during the postoperative period of patients undergoing elective spine surgery by degenerative disc disease. secondary endpoints were pain scores and the presence or absence of adverse effects such as headache, nausea, vomiting, itching, dizziness and drowsiness.

Eligibility criteria:
inclusion criteria: * patients were included, of both genders, aged between 18 and 70 years and american society of anesthesiologists (asa) physical status 1-3 and were eligible for the study exclusion criteria: * patients allergics to duloxetine, ketoralac or fentanyl, pre-existing history of use of illegal substances or alcohol in an abusive manner and abnormal kidney or liver function tests.
evaluation and characterization of behavioural disorders and dementias by the behavioural dysexecutive syndrome inventory (bdsi)

Conditions: Frontotemporal Dementia; Huntington Disease; Alzheimer Disease; Semantic Dementia; Dementia, Vascular

Summary: behavioural disorders are very common right from the initial stage of dementia and contribute to loss of autonomy. behavioural dysexecutive disorders have a particular status due to their prevalence and their diagnostic importance, as they often constitute the initial symptoms of frontotemporal dementia (ftd), semantic dementia (sd) and huntington's disease (hd) and they are classically more frequent in vascular dementia (vad) than in alzheimer's disease (ad). the presence of these disorders at the stage of mild cognitive impairment (mci) has only been partially evaluated and would increase the risk of progression to dementia. these classical data are based on non-standardized assessments and non-validated diagnostic criteria. the groupe de reflexion pour l'evaluation des fonctions exécutives (grefex) has developed a standardized assessment tool for behavioural dysexecutive disorders, the behavioural dysexecutive syndrome inventory (bdsi) and has validated diagnostic criteria for this syndrome.


Eligibility criteria:
inclusion criteria: * support to the consultation memory for a neurological disease ( frontotemporal dementia , vascular dementia , alzheimer's disease , mild cognitive disorder, huntington's disease ( with genetic diagnosis confirmed : number of cag triplets \> 36 symptomatic : uhdrs score ≥5 ) with mms \> 15 * age 40 to 85 years * french * informing reliable * agreeing to participate in the study. exclusion criteria: * presence of other disease disturbing behavior ( current depressive syndrome , schizophrenia, psychosis , past psychiatric disorders requiring a stay \> 2 days in a specialized environment ) or cognition (mental retardation , illiteracy , respiratory failure, kidney , liver , heart ) or preventing the realization of the tests ( perceptual or motor deficit ) intrecérébrale pacing therapy or stem cell transplant , patient protected ( under supervision or guardianship ) , pregnant and / or breastfeeding and lack of consent

Keywords: behavioural disorders
intravesicular onabotulinumtoxin a in interstitial cystitis

Conditions: Interstitial Cystitis

Summary: the purpose of this research study is to identify the optimal usage of onabotulinumtoxin a in interstitial cystitis. onabotulinumtoxin a, more commonly known by the trade name botox®, is a medication that comes from the bacteria clostridium botulinum. it works by blocking the release of the neurotransmitter acetylcholine(a chemical messenger that carries signals between nerve cells and other cells in the body). blocking that neurotransmitter results in decreased muscle activity.

the purpose of this study is to evaluate the efficacy of intravesicular onabotulinumtoxin a injections for the treatment of interstitial cystitis (ic). specifically, we hypothesize that trigonal onabotulinumtoxin a injections is an effective treatment for ic and will result in more subjective and objective symptom relief than posterior wall onabotulinumtoxin a injections.

Eligibility criteria:
inclusion criteria: 1. adult females between the ages of 18 and 80 inclusive 2. patients being treated for ic who are refractory to conservative management and oral therapy. 3. willing and able to initiate catheterization post-treatment exclusion criteria: 1. any history of bladder cancer, uterine cancer, ovarian cancer, vaginal cancer, urethral diverticulum, spinal cord injury, stroke, parkinson's disease, multiple sclerosis, spina bifida, cyclophosphamide treatment, radiation treatment to the pelvis, bladder tuberculosis, genital herpes. 2. currently on or requiring anti-platelet/anti-coagulant concomitant therapy or having been on anti-platelet/ anti-coagulant therapy within the past 3 months 3. pregnancy. pregnancy is an absolute contraindication to undergoing these procedures. thus, as part of their normal pre-operative work up, which is standard of care, pregnancy tests are administered if they are women of child-bearing age, are sexually active, and are within 10 days of the normal menstrual period. if positive, they will be excluded as they will not undergo the procedure. 4. an active urinary tract infection as shown during clean-catch urinalysis at screening visit. subject may be re-screened if uti is successfully treated and urinalysis is negative at rescreening. 5. a history of hypersensitivity or allergy to any botulinum toxin preparation 6. a post-void residual (pvr) urine volume \>200ml at baseline 7. treatment with botulinum toxin during the 12 week period prior to the trial

Keywords: women interstitial cystitis bladder pain syndrome botox onabotulinum toxin a
effect of different exercise modalities training in patients with obstructive sleep apnea.

Conditions: Obstructive Sleep Apnea

Summary: the objective of this study was to compare different exercise modalities (moderate continuous intensity training, high intensity interval training, and inspiratory muscle training) on apnea-hypopnea index and oxidative stress in patients with obstructive sleep apnea.

forty patients with osa aged 20 and 50 years old, dividing into 4 groups (mict, hiit, imt, and con) by stratified (with sex, age, and osa severity) and single random sampling. the mict group received 50 minutes of running at 65-70% of maximum heart rate 3 days/week for 12 weeks. the hiit groups received 28 minutes of running (high intensity at 85-90% of maximum heart rate 2 minutes interval with low intensity 50-55% of maximum heart rate 2 minutes) 3 days/week for 12 weeks. the imt group received powerbreathe ® device, performing 240 breath (8 sets) per day at 50% of maximal inspiratory pressure (mip), 5 days/week for 12 week. the con group did not have any intervention but usual care. data collection was split 2 days (1st day for polysomnography evaluation, and 2nd day for questionnaire, blood collection, body composition, exhaled nitric oxide, pulmonary function, respiratory muscle strength and aerobic capacity). all variables were measured before and after exercise program.

Eligibility criteria:
inclusion criteria: 1. diagnosed with mild (ahi 5-15) or moderate (ahi 15-30) osa, aged between 20 - 50 years. 2. bmi between 18.5 - 24.9 kg/ m2. 3. no history of exercise more than 150 min/week for 4 weeks. 4. no used cpap or discontinue at least 2 weeks. 5. no history for surgery for osa treatment. screened by physician that patients have not had uncontrolled diabetes (blood sugar 180 mg/dl) uncontrolled hypertension (bp 139/89 mmhg) any coronary artery disease any neuromuscular disease chronic obstructive pulmonary disease; copd any cognitive disease other sleep-related disorders cancer 7. not a person with current smoker, menopause or pregnancy. 8. stable medication. 9. willing to participate in this research. exclusion criteria: 1. cannot participate at least 80% of exercise program. 2. inevitable event (injury, sickness, etc.) 3. unwilling to continue this research.

Keywords: hiit pulmonary function sleep exercise polysomnography
observational study to investigate the effectiveness of eprosartan on pulse pressure (teveten_ms)

Conditions: Hypertension

Summary: the study is to identify the effectiveness of eprosartan on pulse pressure in hypertensive patients with metabolic syndrome -definition of pulse pressure (pp): difference between systolic and diastolic blood pressure produced one heart beat.

primary objective -to assess the changes of pulse pressure at 12 weeks secondary objectives * to assess the changes of pulse pressure at 4, 24 weeks * to assess the changes of systolic blood pressure and diastolic blood pressure at each visit * percentage of responder rate\* at each visit and time to get normalized bp from enrollment * responder rate at last visit * to assess iief-5 (5-item version of the international index of erectile function) score at enrollment and 24 weeks (percentage of patients with ed according to iief-5, changes of iief-5 domains) * percentage of patients with erectile dysfunction (ed) according to iief-5 and changes of pp in subgroup (age 65, body mass index (bmi) 23, diabetes mellitus, dyslipidemia, benign prostate hypertrophy) * analysis of correlation between ed and concomitant disease and concomitant medications in patients who received eprosartan * score changes of framingham 10-year coronary heart disease (chd) risk at 1st visit, 4th visit * percentages of eprosartan monotherapy and multiple antihypertensive therapies at enrollment and last visit * reason for treatment discontinuation (inadequate bp control, adverse events, others) * adverse events * responder rate: sbp \<140mmhg and dbp \<90mmhg (sbp \<140mmhg and dbp \<85mmhg for patients with diabetes mellitus)

Eligibility criteria:
inclusion criteria: 1. 20-80 years old patient at the 1st visit 2. patient who is determined to prescribe eprosartan for hypertension (patient with at least one of the following conditions) (1) newly diagnosed hypertension (2) inability to tolerate hypertension (for example: adverse event) (3) lack of response to current antihypertensive medications 3. metabolic syndrome patient (fulfill 3 or more components before enrollment) (1) waist circumference (\>90 for men, \>80 for women) (2) triglycerides (≥150mg/dl) (3) hdl cholesterol (\<40mg/dl for men, \<50mg/dl for women) (4) sbp≥130mmhg or dbp≥85mmhg or on antihypertensive medications) (5) fasting glucose level (≥100mg/dl) or on antidiabetic medications * ms diagnosis origin: korean diabetes association exclusion criteria: 1. patients who is administered with 3 or more than 3 antihypertensive drugs 2. patients who is contraindicated with eprosartan by the product label